alnylam
The Associate Director leads Alnylam’s enterprise audit and inspection program, establishing a unified, risk-based framework for consistent audit execution and global regulatory compliance. The role oversees inspection readiness, audit tools, and cross-functional collaboration to ensure quality oversight and continuous improvement.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
31% above the average for this role
Senior Manager, GxP Audit Program
Insmed Incorporated
Quality Lead Japan
UCB
GXP Audit and Inspection Director
Mundipharma
Audit and Inspection Manager - GxP
Sanofi
Quality Assurance Associate, GxP Audits & Inspection Excellence
Alnylam Pharmaceuticals
Regional Clinical Compliance Inspection Manager
BeOne Medicines